PMID- 24671453
OWN - NLM
STAT- MEDLINE
DCOM- 20141017
LR  - 20211021
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 59
IP  - 9
DP  - 2014 Sep
TI  - Preprocedural rabeprazole treatment before endoscopic submucosal dissection for 
      gastric neoplasms.
PG  - 2243-8
LID - 10.1007/s10620-014-3117-3 [doi]
AB  - BACKGROUND: The maximal effect of proton pump inhibitors (PPI) is reported to 
      take 5 days. However, most current protocols start PPI on the day of gastric 
      endoscopic submucosal dissection (ESD). AIMS: We aimed to evaluate the benefit of 
      5 days pretreatment with oral PPI before ESD to prevent bleeding. METHODS: This 
      was a prospective randomized controlled trial. Patients were administered oral 
      rabeprazole 20 mg or placebo twice daily for 5 days before ESD. Intravenous 
      pantoprazole 40 mg was administered 2 h before ESD and at postprocedure day 1, 
      and then oral rabeprazole 20 mg was administered once daily. Follow-up endoscopy 
      was performed on days 1 and 30. Forty-eight-hour measurement of intragastric pH 
      was performed in 26 patients. The primary endpoint was major bleeding related to 
      ESD. RESULTS: One-hundred and twenty patients were enrolled. Of these, 45 in the 
      pretreatment and 53 in the placebo group were analyzed. Each group had three 
      cases of major bleeding. There were no significant differences in the ulcer 
      healing rate. Intragastric pH percentage times greater than 4, 5, and 6 were 
      86.61 +/- 19.45 %, 83.30 +/- 22.06 %, and 76.86 +/- 25.35 %, respectively, in the 
      pretreatment and 85.54 +/- 19.45 %, 84.08 +/- 27.11 %, and 81.53 +/- 27.81 %, 
      respectively, in the placebo group, without significant differences. CONCLUSIONS: 
      Preprocedural administration of rabeprazole offers no additional benefit over 
      postprocedural administration alone in preventing major bleeding after gastric 
      ESD.
FAU - Baeg, Myong Ki
AU  - Baeg MK
AD  - Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's 
      Hospital, College of Medicine, The Catholic University of Korea, # 505, 
      Banpo-Dong, Seocho-Gu, Seoul, 137-701, South Korea.
FAU - Choi, Myung-Gyu
AU  - Choi MG
FAU - Moon, Seong Jin
AU  - Moon SJ
FAU - Lim, Chul-Hyun
AU  - Lim CH
FAU - Kim, Jin Su
AU  - Kim JS
FAU - Cho, Yu Kyung
AU  - Cho YK
FAU - Park, Jae Myung
AU  - Park JM
FAU - Lee, In Seok
AU  - Lee IS
FAU - Kim, Sang Woo
AU  - Kim SW
FAU - Choi, Kyu Yong
AU  - Choi KY
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140327
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
RN  - D8TST4O562 (Pantoprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage
MH  - Aged
MH  - Dissection/adverse effects
MH  - Female
MH  - Gastric Mucosa/surgery
MH  - Gastrointestinal Hemorrhage/etiology/*prevention & control
MH  - Gastroscopy
MH  - Humans
MH  - Hydrogen-Ion Concentration/drug effects
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic
MH  - Pantoprazole
MH  - Postoperative Hemorrhage/etiology/*prevention & control
MH  - *Preoperative Care
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Rabeprazole/*administration & dosage
MH  - Second-Look Surgery
MH  - Stomach/physiopathology
MH  - Stomach Neoplasms/*surgery
MH  - Wound Healing/drug effects
EDAT- 2014/03/29 06:00
MHDA- 2014/10/18 06:00
CRDT- 2014/03/28 06:00
PHST- 2014/01/15 00:00 [received]
PHST- 2014/03/13 00:00 [accepted]
PHST- 2014/03/28 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/10/18 06:00 [medline]
AID - 10.1007/s10620-014-3117-3 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2014 Sep;59(9):2243-8. doi: 10.1007/s10620-014-3117-3. Epub 2014 Mar 
      27.